In 2005 the European Respiratory Society (ERS), in collaboration with The European Society for Clinical Microbiology and Infectious Diseases (ESCMID), published guidelines on the management of lower respiratory tract infections (LRTI) in adults [1]. This document was based on published scientific literature up to the end of 2002. We have now updated these guidelines to include publications to May 2010. The Taskforce responsible for guideline development has been sponsored by the ERS and ESCMID. Members of the Taskforce are members of the sponsoring ERS and/or ESCMID.
Our objective is to provide evidence-based recommendations for the most common management questions occurring in routine clinical practice in the management of adult patients with LRTI. The target audience for the guidelines is thus all those whose routine practice includes the management of adult LRTI.
This document begins with definitions and background sections on microbial cause, resistance and pharmacokinetics/pharmacodynamics, with conventional referencing. The guideline section captures management outside hospital, management inside hospital (including community-acquired pneumonia (CAP), acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and acute exacerbations of bronchiectasis) and prevention. The guidelines are about the management of infection. This means that for conditions such as AECOPD, aspects of management that are unreleated to infection (e.g. use of steroids or bronchodilators) are not included. It contains the graded recommendations but also the background information for each recommendation, with details about each new cited reference and the evidence grades. Because this is an update, original data and publications have usually not been repeated and the reader is referred to the original publication for this. As this is an update using the same methodologies, the layout of the document, including text, recommendations and evidence tables, is the same as in 2005.
下呼吸道感染吃什么药 2011欧洲下呼吸道感染攻略
精彩推荐
- 辅助驾驶谁更“老司机”?问界新M5才是真正懂你的出行伙伴

近期,2025年相关媒体发布的汽车辅助驾驶金字塔分级排行直接将华为乾崑智驾ADS划入极致尖顶区间,独享80-100分评分。而特斯拉与众多品牌则处于综合优选与安全基线区间。01...详细
- 万台下线里程碑背后:尊界S800如何重写豪华汽车市场规则

2025年12月16日,尊界S800第10000台量产车驶下生产线。这一刻,其意义早已超越了一款车型的成功,它意味着,在曾被西方品牌牢牢把持的超豪华权力堡垒中,中国品牌不仅成功...详细
- 尊界S800万台量产下线,开启中国品牌在百万级市场的“加速度”

2025年12月16日,尊界S800迎来第10,000台量产车正式下线。这一数字,在中国品牌百万级超豪华轿车的发展历程中,具有标志性意义。它不仅意味着中国高端制造成功切入曾被国际...详细
- 无惧寒冬的全能搭档:问界新M5 Ultra以卓越性能化解出行困扰

岁暮天寒,晨雾锁城,路面如镜这些冬季日常的出行挑战,不仅考验着驾驶者的技术与耐心,更在检验着一辆车的真实底色。当许多人仍在为冬季通勤的种种不便而烦恼时,众多问界...详细
本周热门
- 同仁堂健康双十一活动开启 “象食养医”倡导从健康的时候就关注健康

如果你想了解自己身体的秘密,让健康成为日常的生活方式,保持年轻的状态,实现抗衰老,逆生长的美好愿望,那么今年双十一的这场活动你一定不要错过。11月1日,同仁堂健康...详细





